stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Operating cash flow
Madrigal Pharmaceuticals, Inc.'s operating cash flow for fiscal 2025 was −$189.6M, compared with −$455.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$157.0M. Over the past ten years it has ranged from −$455.6M (fiscal 2024) to −$3.1M (fiscal 2015); the current reading is higher than 36% of that period. Madrigal Pharmaceuticals, Inc. ranks 513th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$189.6M | — |
| FY2024 | −$455.6M | — |
| FY2023 | −$324.2M | — |
| FY2022 | −$224.9M | — |
| FY2021 | −$183.9M | — |
| FY2020 | −$157.6M | — |
| FY2019 | −$41.6M | — |
| FY2018 | −$25.5M | — |
| FY2017 | −$22.3M | — |
| FY2016 | −$17.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $120.6M | 416.76% |
| Jun 2026 | $23.3M | — |
| Mar 2026 | −$167.4M | — |
| Dec 2025 | −$133.5M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $323.9M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. | −$157.0M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$281.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement